Core Viewpoint - The A-share market is experiencing a strong performance in flu-related stocks, driven by expectations of a flu outbreak in the upcoming winter season [1] Group 1: Market Performance - Flu concept stocks in the A-share market have shown significant gains, with Te Yi Pharmaceutical hitting the daily limit, Tai Long Pharmaceutical and Nanxin Pharmaceutical rising over 7%, Weikang Pharmaceutical increasing over 5%, and Peking University Pharmaceutical up nearly 4% [1] - Yiling Pharmaceutical has also seen an increase of almost 4% [1] Group 2: Health Forecast - The China Center for Disease Control and Prevention (CDC) predicts that the peak of the flu epidemic in China this autumn and winter may occur in mid-December to early January [1] - The CDC is actively monitoring and assessing flu activity across the country, indicating that the overall flu activity in China is currently on the rise [1] - The H3N2 subtype of the influenza virus accounts for over 95% of the cases, with a small presence of H1N1 and B-type influenza viruses circulating simultaneously [1]

Core Viewpoint - The flu sector has experienced a significant rally, with notable stock price increases among several pharmaceutical companies [1] Company Summaries - Special One Pharmaceutical has reached its daily limit increase in stock price [1] - Nanxin Pharmaceutical's stock has risen by over 6% [1] - Tailong Pharmaceutical, Hendi Pharmaceutical, and Zhongsheng Pharmaceutical have also seen stock price increases [1]

Core Viewpoint - TaiLong Pharmaceutical has shown a significant stock price increase of 36.94% year-to-date, with recent trading activity indicating positive market sentiment and liquidity [1][2]. Financial Performance - For the period from January to September 2025, TaiLong Pharmaceutical reported a revenue of 1.187 billion yuan, representing a year-on-year decrease of 11.47%. The net profit attributable to shareholders was 25.33 million yuan, down 12.36% compared to the previous year [2]. - The company has cumulatively distributed 112 million yuan in dividends since its A-share listing, with 15.53 million yuan distributed over the last three years [3]. Stock Market Activity - As of November 11, TaiLong Pharmaceutical's stock price was 6.97 yuan per share, with a market capitalization of 4 billion yuan. The stock experienced a trading volume of 50.41 million yuan and a turnover rate of 1.28% [1]. - The stock has seen a net inflow of 2.36 million yuan from main funds, with large orders accounting for 22.95% of total purchases [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for TaiLong Pharmaceutical was 40,400, a decrease of 1.08% from the previous period. The average number of tradable shares per shareholder increased by 1.09% to 14,190 shares [2]. - Among the top ten circulating shareholders, Guangfa Pension Index A held 2.9719 million shares, a decrease of 264,000 shares from the previous period, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF entered as a new shareholder with 2.8616 million shares [3].

Core Viewpoint - Tai Long Pharmaceutical announced the completion and termination of its third employee stock ownership plan, with all shares held under this plan sold [1] Summary by Relevant Sections - **Company Announcement** - Tai Long Pharmaceutical Co., Ltd. has fully sold all shares held under its third employee stock ownership plan [1] - The implementation of the third employee stock ownership plan has been completed and is now terminated [1] - **Regulatory Compliance** - The company’s actions are in accordance with the "Guidance on the Pilot Implementation of Employee Stock Ownership Plans for Listed Companies" and the "Self-Regulatory Guidelines for Listed Companies on the Shanghai Stock Exchange" [1] - The termination of the plan follows the relevant regulations outlined in the third employee stock ownership plan documentation [1]

河南太龙药业股份有限公司 2025 年第四次临时股东会会议资料 2025 年 11 月 目 录 | 2025 | 年第四次临时股东会会议须知 2 | | --- | --- | | 2025 | 年第四次临时股东会会议议程 3 | | 议案一 | 关于 2025 年前三季度利润分配方案的议案 4 | | 议案二 | 关于拟申请注册发行中期票据的议案 5 | 1 2025 年第四次临时股东会会议须知 为维护投资者的合法权益，确保本次股东会顺利进行，河南太龙 药业股份有限公司（以下简称"公司"）根据《中华人民共和国公司 法》《上市公司股东会规则》以及《公司章程》等有关规定，制定会 议须知如下： 一、本次股东会设秘书处，负责会议组织工作和处理相关事宜。 二、为保证本次股东会的严肃性和正常秩序，除依法出席会议的 公司股东（或股东代理人）、董事、高级管理人员、聘请的律师及相 关工作人员外，公司有权依法拒绝其他人士入场。 三、出席会议的股东（或股东代理人）必须在会议召开前十分钟 向股东会秘书处办理签到、登记手续。 四、股东（或股东代理人）参加股东会依法享有发言权、质询权、 表决权等权利。股东需要发言或就有关问题进行提问的 ...

Core Viewpoint - Tai Long Pharmaceutical (600222.SH) has completed the sale of all 10.8461 million shares held under its third employee stock ownership plan, which has now been terminated [1] Summary by Relevant Sections - **Employee Stock Ownership Plan** - The third employee stock ownership plan has been fully executed and automatically terminated as of the announcement date [1] - The total number of shares sold under this plan amounts to 10.8461 million [1] - **Asset Management** - All assets held under the employee stock ownership plan are now converted into monetary assets [1] - The company will proceed with the liquidation and distribution of the related assets from the third employee stock ownership plan [1]

Core Viewpoint - Tailong Pharmaceutical (600222.SH) announced the complete sale of 10.8461 million shares held under its third employee stock ownership plan as of the announcement date [1] Group 1 - The third employee stock ownership plan has successfully sold all shares it held [1] - The total number of shares sold amounts to 10.8461 million [1]

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-057 河南太龙药业股份有限公司 关于第三期员工持股计划股票出售完毕暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）第三期员工持 股计划所持有的公司股票已全部出售完毕，根据《关于上市公司实施 员工持股计划试点的指导意见》《上海证券交易所上市公司自律监管 指引第 1 号——规范运作》及《河南太龙药业股份有限公司第三期员 工持股计划》（以下简称"第三期员工持股计划"）等相关规定，第 三期员工持股计划实施完毕并终止。现将相关情况公告如下： 一、第三期员工持股计划基本情况 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-057 （www.sse.com.cn）披露的临 2022-023 号、临 2022-035 号、临 2022-077 号等相关公告。 2、2022 年 11 月 22 日，公司收到中国证券登记结算有限责任公 司出具的《过户登记确认书》，公司回购专用证券账户中所持有的 10, ...

Core Insights - TaiLong Pharmaceutical (600222.SH) reported a total revenue of 1.187 billion yuan for Q3 2025, ranking 29th among disclosed peers, which is a decrease of 154 million yuan or 11.47% year-on-year [1] - The net profit attributable to shareholders was 25.33 million yuan, ranking 41st among peers, down by 3.57 million yuan or 12.36% compared to the same period last year [1] - The company experienced a net cash outflow from operating activities of 88.99 million yuan, ranking 55th among peers, but this represents an increase of 7.73 million yuan year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 55.88%, ranking 53rd among peers, which is an increase of 2.12 percentage points from the previous quarter but a decrease of 0.63 percentage points year-on-year [3] - The gross profit margin is 24.29%, ranking 54th among peers, down by 0.40 percentage points from the previous quarter and down by 2.20 percentage points year-on-year [3] - The return on equity (ROE) is 1.59%, ranking 42nd among peers, which is a decrease of 0.25 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.05 yuan, ranking 39th among peers, which is a decrease of 0.01 yuan or 11.75% year-on-year [3] - The total asset turnover ratio is 0.33 times, ranking 32nd among peers, down by 0.04 times year-on-year, representing a decline of 10.57% [3] - The inventory turnover ratio is 2.12 times, ranking 14th among peers, which is an increase of 0.10 times or 5.03% year-on-year [3] Shareholder Structure - The number of shareholders is 40,400, with the top ten shareholders holding 168 million shares, accounting for 29.31% of the total share capital [3] - The largest shareholder is Zhengzhou TaiRong Industrial Investment Co., Ltd., holding 14.37% of the shares [3] - Other notable shareholders include Zhengzhou Zhongsheng Industrial Group Co., Ltd. with 8.71% and Wu Lan with 1.38% [3]

Group 1 - The core viewpoint of the article is that Tailong Pharmaceutical (SH 600222) held its 10th fourth board meeting on October 28, 2025, to discuss the proposal for the fourth extraordinary shareholders' meeting in 2025 [1] - For the first half of 2025, Tailong Pharmaceutical's revenue composition is as follows: 70.59% from pharmaceutical manufacturing, 14.71% from pharmaceutical research and development, 14.42% from pharmaceutical distribution, and 0.28% from other businesses [1] - As of the report date, Tailong Pharmaceutical has a market capitalization of 3.7 billion yuan [1]